Halbert Hargrove Global Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1
Closed -$524 – 625
2026
Q2
$524 Buy
+1
New +$681 ﹤0.01% 523
2025
Q4
– Sell
-4
Closed -$2.25K – 668
2025
Q3
$2.25K Buy
+4
New +$2.26K ﹤0.01% 542
2025
Q2
– Sell
-4
Closed -$2.54K – 579
2025
Q1
$2.54K Buy
+4
New +$2.75K ﹤0.01% 378
2015
Q3
– Sell
-628
Closed -$320K – 152
2015
Q2
$320K Sell
628
-348
-36% -$170K 0.08% 129
2015
Q1
$441K Buy
976
+370
+61% +$157K 0.14% 105
2014
Q4
$249K Sell
606
-12
-2% -$4.72K 0.12% 111
2014
Q3
$223K Sell
618
-241
-28% -$80.8K 0.06% 131
2014
Q2
$243K Buy
859
+92
+12% +$27.3K 0.07% 102
2014
Q1
$230K Buy
+767
New +$236K 0.07% 106

Other funds holding REGN

Halbert Hargrove Global Advisors's REGN Position: Q3 2026 in Review

Halbert Hargrove Global Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2026, closing a stake of 1 share — an estimated $524 sold.

Halbert Hargrove Global Advisors first reported a position in REGN in Q1 2014 and held it in 9 quarters. The position peaked at $441K in Q1 2015. 1,427 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Halbert Hargrove Global Advisors reported no remaining Regeneron Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Halbert Hargrove Global Advisors sold 1 Regeneron Pharmaceuticals share in Q3 2026, an estimated $524.
  • Halbert Hargrove Global Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 9 quarters.
  • Halbert Hargrove Global Advisors's Regeneron Pharmaceuticals position peaked at $441K in Q1 2015.
  • 1,427 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Halbert Hargrove Global Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.